壮肾固精方联合西药治疗IgA肾病临床研究
DOI:
CSTR:
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

R692.6

基金项目:

2022年度珠海市社会发展领域科技计划项目(2220004000347)


Clinical Study on Combination Use of Zhuangshen Gujing Prescription and Conventional Western Medicine for IgA Nephropathy
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:观察壮肾固精方联合西药治疗免疫球蛋白A(IgA)肾病的临床疗效。方法:纳入2023年1—12月 在广东省中医院珠海医院及珠海市人民医院就诊的IgA肾病患者共72例,按不同的治疗方法分为对照组及治疗 组,各36例。对照组给予西药常规治疗,治疗组在对照组的基础上加用壮肾固精方加减治疗。疗程均为24周, 比较2组治疗前后24小时尿蛋白定量 (24 h-UTP)、尿微量白蛋白肌酐比值 (UACR)、血肌酐 (SCr)、尿素 (BUN)、估算肾小球滤过率 (eGFR) 的变化情况,并评估其临床疗效及用药安全性。结果:治疗组总有效 率为88.89%(32/36),对照组为77.78%(28/36),组间比较,差异无统计学意义(P>0.05)。治疗前,2组肾 功能相关指标BUN、SCr、eGFR、24 h-UTP、UACR水平比较,差异无统计学意义(P>0.05)。治疗后,治疗 组 SCr 水平低于对照组,eGFR 水平高于对照组,差异均有统计学意义 (P<0.05);2 组 BUN、24 h-UTP、 UACR水平比较,差异无统计学意义(P>0.05)。2组治疗前后安全性指标K + 、Alb、ALT、AST水平比较,差 异均无统计学意义(P>0.05)。治疗组不良反应发生率为11.11%(4/36),对照组为19.44%(7/36),2组比较, 差异无统计学意义(P>0.05)。结论:壮肾固精方联合西药常规治疗IgA肾病可提高临床疗效,在协同降低蛋 白尿的同时延缓eGFR的下降,有效保护肾功能,且安全性良好。

    Abstract:

    Abstract:Objective:To observe the clinical effect of the combination use of Zhuangshen Gujing Prescription and conventional western medicine on IgA nephropathy. Methods:A total of 72 IgA nephropathy patients who were treated in Zhuhai Hospital of Guangdong Provincial Hospital of Chinese Medicine,and Zhuhai People's Hospital from January 2023 to December 2023 were included. They were divided into the control group and the treatment group according to different treatment methods,with 36 cases in each group. The control group was given conventional western medicine for treatment,and the treatment group was additionally treated with modified Zhuangshen Gujing Prescription based on the treatment in the control group. The course of treatment was 24 weeks. The changes in 24-hour urine total protein(24 h-UTP),urinary albumin-to-creatinine ratio(UACR),serum creatinine(SCr),blood urea nitrogen (BUN)and estimated glomerular filtration rate (eGFR)were compared between the two groups before and after treatment,and the clinical effects and safety of medication were evaluated. Results:The total effective rate was 88.89 (32/36)in the treatment group and 77.78(28/36)in the control group;there were no significant differences between the two groups(P>0.05).Before treatment,there was no significant difference being found in the comparisons of the levels of kidney function indicators of BUN,SCr,eGFR,24 h-UTP and UACR between the two groups(P>0.05). After treatment,the SCr level in the treatment group was lower than that in the control group,and the eGFR level was higher than that in the control group,differences being significant(P<0.05);there was no significant difference being found in the comparisons of the levels of BUN,24 h-UTP and UACR between the two groups(P>0.05). Before and after treatment,there were no significant differences being found in the levels of safety indicators of K + ,Alb,ALT and AST between the two groups(P>0.05). The incidence of adverse reactions was 11.11%(4/36)in the treatment group and 19.44%(7 / 36)in the control group, there being no significant difference between the two groups (P>0.05). Conclusion: The therapy of Zhuangshen Gujing Prescription combined with conventional western medicine can improve the clinical effect on IgA,delay the decline of eGFR while reducing proteinuria,and effectively protect the kidney function with good safety.

    参考文献
    相似文献
    引证文献
引用本文

许俊杰,刘立昌,张睿,何培华,洪炜鸿,王利纯,金玉燕,曾佳豪.壮肾固精方联合西药治疗IgA肾病临床研究[J].新中医,2025,57(16):45-49

复制
分享
相关视频

文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期: 2025-08-26
  • 出版日期:
文章二维码